Utz Brands Reports Third Quarter 2025 Results Raises Organic Net Sales Growth Guidance and Announces California Expansion Hanover, PA – October 30, 2025 – Utz Brands, Inc. (NYSE: UTZ) ("Utz" or the "Company"), a leading U.S. manufacturer of branded Salty Snacks and a small-cap growth and value Staples equity, today reported financial results for the Company's third fiscal quarter ended September 28, 2025. 3Q'25 Summary (1) (1) All comparisons for the third quarter of 2025 are to the third quarter of 2024 (e ...

PARSIPPANY, NJ - October 30, 2025 - PBF Energy Inc. (NYSE:PBF) today reported third quarter 2025 income from operations of $285.9 million as compared to loss from operations of $386.3 million for the third quarter of 2024. Excluding special items, third quarter 2025 loss from operations was $27.1 million as compared to loss from operations of $231.5 million for the third quarter of 2024. PBF Energy Announces Third Quarter 2025 Results and Declares Dividend of $0.275 per Share Mr. Lucey concluded, "Looking f ...

Press Release October 30, 2025 HF Sinclair Reports 2025 Third Quarter Results and Announces Regular Cash Dividend Dallas, Texas, October 30, 2025 ‑ HF Sinclair Corporation (NYSE and NYSE Texas, Inc.: DINO) ("HF Sinclair" or the "Company") today reported Net income attributable to HF Sinclair stockholders of $403 million, or $2.15 per diluted share, for the quarter ended September 30, 2025, compared to Net loss attributable to HF Sinclair stockholders of $76 million, or $(0.40) per diluted share, for the qua ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-40671 NUVALENT, INC. (Exact name of registrant as specified in its charter) D ...

Earnings Performance - CMS Energy reported earnings per share of $0.92 for Q3 2025, up from $0.84 in Q3 2024, with adjusted earnings per share of $0.93 compared to $0.84 in the same quarter last year[1]. - For the first nine months of 2025, the company reported earnings per share of $2.59, an increase from $2.45 in the same period of 2024, with adjusted earnings per share of $2.66 compared to $2.47[1][2]. - CMS Energy raised its 2025 adjusted earnings guidance to a range of $3.56 to $3.60 per share, up from the previous range of $3.54 to $3.60[2]. - The company initiated 2026 adjusted earnings guidance of $3.80 to $3.87 per share, reaffirming long-term adjusted EPS growth of 6 to 8 percent[2]. Revenue and Income - Operating revenue for Q3 2025 was $2,021 million, compared to $1,743 million in Q3 2024, while operating income increased to $481 million from $367 million[9]. - Net income attributable to CMS Energy for Q3 2025 was $277 million, compared to $253 million in Q3 2024, with net income available to common stockholders at $275 million versus $251 million[9]. Assets and Liabilities - Total assets as of September 30, 2025, were $38,008 million, an increase from $35,920 million at the end of 2024[11]. - CMS Energy's total liabilities and equity as of September 30, 2025, were $38,008 million, reflecting an increase from $35,920 million at the end of 2024[11]. Cash Flow - Cash and cash equivalents at the end of Q3 2025 were $432 million, down from $467 million at the end of Q3 2024[14]. - The company reported net cash provided by operating activities of $1,757 million for the first nine months of 2025, compared to $1,967 million in the same period of 2024[14].

Financial Performance - Total sales for Q3 2025 reached $17,276 million, a 4% increase compared to Q3 2024[2] - Net income attributable to Merck for Q3 2025 was $5,785 million, reflecting an 83% increase year-over-year[2] - The earnings per share for Q3 2025 was $2.32, an increase of 87% from $1.24 in Q3 2024[2] - The income before taxes for Q3 2025 was $6,745 million, a 65% increase compared to $4,090 million in Q3 2024[2] - The tax rate for Q3 2025 was 14.2%, compared to 22.7% in Q3 2024[2] - The company reported a significant increase in net income for the year-to-date period, totaling $15,301 million, a 14% increase from $13,389 million in the same period last year[2] Sales Performance - Year-to-date sales for 2025 reached $48,611 million, showing no change from the same period in 2024[2] - Total sales for Q3 2025 reached $17,276 million, a 4% increase from $16,657 million in Q3 2024[10] - Pharmaceutical sales were $15,611 million, up 4% from $14,943 million in the same quarter last year[10] - Total sales for September YTD 2025 reached $48,611 million, a slight increase from $48,544 million in 2024[19] - Pharmaceutical sales were $43,299 million in September YTD 2025, remaining relatively stable compared to $43,358 million in 2024[19] Product Sales - Keytruda sales increased by 10% to $8,142 million compared to $7,429 million in Q3 2024[10] - Alliance revenue from Lynparza rose by 12% to $379 million, while Lenvima's revenue increased by 3% to $258 million[10] - Total vaccines sales decreased to $3,370 million from $3,675 million, a decline of 8% year-over-year[14] - Diabetes sales grew to $703 million, up from $592 million, reflecting a 19% increase[16] - Animal health segment reported sales of $1,615 million, a 9% increase from $1,487 million in the previous year[10] - Livestock sales increased by 16% to $1,023 million, while companion animal sales slightly decreased by 2% to $592 million[10] - Keytruda sales increased by 8% to $23,303 million in September YTD 2025, up from $21,646 million in 2024[19] - Gardasil/Gardasil 9 sales decreased significantly by 40% to $4,202 million in September YTD 2025, down from $7,032 million in 2024[19] - Total vaccines sales were $8,347 million in September YTD 2025, down from $10,755 million in 2024, reflecting a decline of 22.4%[23] - Total diabetes sales increased by 11.2% to $2,283 million in September YTD 2025, compared to $2,053 million in 2024[25] - Alliance revenue for Koselugo was $301 million in September YTD 2025, significantly higher than $114 million in 2024[25] Market Performance - The U.S. market contributed $27,371 million to total sales in September YTD 2025, a 14% increase from $24,089 million in 2024[19] - International sales decreased by 13% to $21,240 million in September YTD 2025, down from $24,455 million in 2024[19] - U.S. pharmaceutical sales increased by 15% year-over-year to $9.493 billion in Q3 2025, up from $8.227 billion in Q3 2024[28] - Japan's pharmaceutical sales decreased by 25% year-over-year to $693 million in Q3 2025, down from $919 million in Q3 2024[28] - Sales in China dropped significantly by 62% year-over-year to $377 million in Q3 2025, compared to $996 million in Q3 2024[28] Expenses and Income - Research and development expenses decreased by 28% in Q3 2025, totaling $4,234 million compared to $5,862 million in Q3 2024[2] - The cost of sales for Q3 2025 was $3,855 million, a decrease of 6% from $4,080 million in Q3 2024[2] - Selling, general and administrative expenses for Q3 2025 were $2,633 million, down 4% from $2,731 million in Q3 2024[2] - Interest income for Q3 2025 was $(96) million, compared to $(127) million in Q3 2024[31] - Total net other income/expense for Q3 2025 was $(238) million, an increase in loss compared to $(162) million in Q3 2024[31] - The company reported a total interest expense of $327 million in Q3 2025, slightly down from $330 million in Q3 2024[31] - Exchange losses increased to $56 million in Q3 2025 from $33 million in Q3 2024[31] Future Outlook - The company anticipates continued growth in key therapeutic areas and plans to expand its market presence through new product launches and strategic partnerships[10] - The full-year pharmaceutical sales guidance for 2025 is projected at $57.400 billion, reflecting a slight increase from $57.000 billion in 2024[28]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Utz Brands, Inc. Delaware 001-38686 85-2751850 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 900 High ...

Financial Performance - Cash, cash equivalents, and marketable securities were $943.1 million as of September 30, 2025, sufficient to fund operations into 2028[13]. - Research and development expenses for Q3 2025 were $83.8 million, compared to $60.6 million in Q3 2024, reflecting a 38.2% increase[13]. - General and administrative expenses for Q3 2025 were $28.9 million, up from $15.8 million in Q3 2024, representing an 83.5% increase[13]. - The net loss for Q3 2025 was $122.4 million, compared to a net loss of $84.3 million in Q3 2024, indicating a 45% increase in losses[13]. - Total stockholders' equity as of September 30, 2025, was $845.4 million, down from $1,069.8 million at the end of 2024[19]. Clinical Development - The company completed its rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC[4]. - The company is on track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC by year-end 2025[3]. - The company is progressing with the ALKAZAR Phase 3 trial for TKI-naïve patients with advanced ALK-positive NSCLC[8]. - Preliminary clinical data for neladalkib showed encouraging activity in advanced ALK-positive solid tumors beyond NSCLC[3]. - The company presented new preclinical data for NVL-330, indicating a favorable profile for HER2-altered NSCLC[8].

Financial Performance - Q3 2025 revenue reached $1.96 billion, an increase of 28.3% year-over-year, or 27.0% in constant currency[3] - GAAP net loss narrowed to $(760) million, or $(6.01) per share, improving by $445 million or $3.70 per share year-over-year[3] - Adjusted net income was $27 million, or $0.20 per share, down $7 million or $0.05 per share year-over-year[3] - Operating cash flow increased to $159 million, up $43 million year-over-year, while free cash flow rose to $131 million, up $24 million year-over-year[3] - Total revenues for Q3 2025 were $1,961 million, a 28.4% increase from $1,528 million in Q3 2024[18] - Net loss for Q3 2025 was $760 million, compared to a net loss of $1,205 million in Q3 2024, representing a 36.9% improvement[21] - The company reported a comprehensive loss of $769 million for Q3 2025, compared to a comprehensive loss of $1,032 million in Q3 2024, indicating a 25.5% reduction[21] - Reported net loss for Q3 2025 was $760 million, resulting in a diluted EPS of $(6.01), compared to a net loss of $1,205 million and diluted EPS of $(9.71) in Q3 2024[75] - Adjusted net income for Q3 2025 was $27 million, with an adjusted EPS of $0.20, while adjusted net income for Q3 2024 was $34 million with an adjusted EPS of $0.25[75] Revenue Segments - IT Solutions segment revenue grew by 162.8% year-over-year, reaching $226 million[6] - Total revenues for the Print and Other segment reached $1,739 million in Q3 2025, a 20.6% increase from $1,442 million in Q3 2024[46] - Equipment sales for Q3 2025 were $383 million, a 13.0% increase in actual currency and 12.1% in constant currency compared to Q3 2024, benefiting from the Lexmark acquisition by 26.0 percentage points[25] - Post-sale revenue reached approximately $1.6 billion, up 32.7% in actual currency and 31.3% in constant currency year-over-year, with Lexmark and ITsavvy contributing 30.2 and 10.3 percentage points respectively[25] - The IT Products category within IT Solutions saw a 200.0% increase in revenue to $165 million in Q3 2025[52] - Post-sale revenue for Q3 2025 was $1,578 million, a 32.7% increase compared to $1,189 million in Q3 2024[94] Cost and Expenses - Research, development, and engineering expenses increased to $74 million in Q3 2025 from $45 million in Q3 2024, a 64.4% rise[18] - Total liabilities increased to $9,474 million as of September 30, 2025, compared to $7,061 million at the end of 2024, a 34.3% increase[22] - The company incurred $467 million in tax expense related to the establishment of a valuation allowance against certain deferred tax assets in Q3 2025[78] - Restructuring and related costs for Q3 2025 amounted to $59 million, compared to $56 million in Q3 2024[75] - The company incurred approximately $230 million in non-financing interest expense related to the Lexmark acquisition financing[88] Guidance and Projections - 2025 guidance revised to 13% revenue growth in constant currency, down from 16-17%[11] - Adjusted operating margin guidance lowered to around 3.5%, down from around 4.5%[11] - Free cash flow guidance reduced to around $150 million, down from around $250 million[11] - Xerox expects 2025 revenue growth of 13% in constant currency, with an adjusted operating income margin of approximately 3.5% and free cash flow of around $150 million[25] - The overall segment profit for 2025 is projected to be $184 million, with a total revenue of $3,978 million[54] Acquisitions and Integration - Lexmark integration is ahead of plan, with cost synergies now forecasted to be at least $300 million, an increase of $50 million from previous estimates[4] - The Lexmark acquisition was completed on July 1, 2025, for approximately $1.5 billion, including cash of $811 million and the assumption of $323 million in debt[26] - Xerox anticipates over $1 per share of accretion from the Lexmark transaction, with no material impact from proposed U.S. tariffs due to Lexmark's manufacturing capabilities in Mexico[27] - The acquisition of ITsavvy has led to a reassessment of reportable segments, now categorized as Print and Other, and IT Solutions[111] Market Conditions and Strategy - The company experienced delays in purchasing decisions among clients due to macroeconomic challenges, particularly affecting transactional Print equipment revenues[24] - Actions taken through the Reinvention strategy have provided Xerox with a flexible operating structure to adapt to market uncertainties[24] - The company is focused on expanding its market presence through strategic acquisitions and enhancing its product offerings[51] - Forward-looking statements indicate potential risks including global macroeconomic conditions and integration challenges with recent acquisitions[57] Other Financial Metrics - Adjusted operating income for Q3 2025 was $65 million, down $15 million from Q3 2024, primarily due to lower gross profit and unfavorable revenue mix[25] - Adjusted operating income for FY 2025 is projected to be around $245 million, with an adjusted margin of approximately 3.5%[86] - Total gross profit for Q3 2025 was $445 million, down from $495 million in Q3 2024, leading to a total gross margin of 22.7%[94] - Adjusted gross profit for Q3 2025 was $566 million, with a margin of 28.9%, down from $495 million and 32.4% in Q3 2024[83] - The company declared dividends of $0.025 per common share for Q3 2025, down from $0.25 in Q3 2024[109]

Financial Performance - Total revenues for Q3 2025 were $311 million, an increase of $28 million or 10% compared to Q3 2024, driven by connected devices and technical services[3]. - Non-GAAP net income for Q3 2025 was $24 million, or $0.51 per diluted share, compared to $26 million, or $0.56 per diluted share in Q3 2024[4]. - Non-GAAP EBITDA for Q3 2025 was $41 million, up from $39 million in Q3 2024[5]. - Total revenues for Q3 2025 reached $310.6 million, a 10% increase from $282.4 million in Q3 2024[31]. - Product revenues increased to $177.5 million in Q3 2025, up from $158.4 million in Q3 2024, representing a growth of 12%[31]. - Service revenues rose to $133.1 million in Q3 2025, compared to $124.1 million in Q3 2024, marking a growth of 7%[31]. - Gross profit for Q3 2025 was $134.5 million, up from $122.3 million in Q3 2024, reflecting a gross margin improvement[31]. - Net income for Q3 2025 was $5.5 million, down from $8.6 million in Q3 2024, resulting in a diluted net income per share of $0.12[31]. - GAAP net income for Q3 2025 was $5,462,000, a decrease from $8,630,000 in Q3 2024, while non-GAAP net income increased to $23,526,000 from $26,070,000[39]. - Non-GAAP EBITDA for the nine months ended September 30, 2025, was $103,100,000, up from $89,351,000 in the same period of 2024, reflecting a margin of 11.8% compared to 11.1%[39]. Cash and Debt Management - Cash and cash equivalents as of September 30, 2025, were $180 million, with total debt of $167 million and total assets of $1.9 billion[6]. - The company repaid $175 million of convertible senior notes and repurchased approximately 1,987,000 shares for about $62 million during Q3 2025[7]. - Cash and cash equivalents at the end of the period decreased to $180,053 thousand as of September 30, 2025, from $570,628 thousand at the end of September 2024, a decline of 68.4%[35]. - Net cash provided by operating activities for the nine months ended September 30, 2025, was $96,946 thousand, down from $131,407 thousand in 2024, a decrease of 26.2%[35]. - GAAP net cash provided by operating activities for Q3 2025 was $28,267,000, an increase from $22,754,000 in Q3 2024, while non-GAAP free cash flow rose to $13,986,000 from $9,418,000[42]. Operational Highlights - The company is focused on transforming into an intelligent medication management technology company to enhance customer experience and drive long-term stakeholder value[2]. - Omnicell's Specialty Pharmacy Services business received Healthcare Management Certification, affirming its commitment to patient-centered services[13]. - New innovations for autonomous medication management will be showcased at the ASHP Midyear 2025 Clinical Meeting in December 2025[13]. - Research and development expenses for Q3 2025 were $24.0 million, compared to $21.2 million in Q3 2024, indicating a focus on innovation[31]. - The company continues to exclude non-GAAP adjustments related to share-based compensation and restructuring costs to provide a clearer picture of core operating results[22][23]. - Omnicell's management emphasizes the importance of non-GAAP financial measures for evaluating performance and making operational decisions[24]. Guidance and Projections - For full year 2025, total revenues are guided to be between $1.177 billion and $1.187 billion, with non-GAAP EBITDA expected between $140 million and $146 million[11]. - Product bookings for 2025 are projected to be between $500 million and $550 million, with annual recurring revenue expected between $610 million and $630 million[11]. Asset and Liability Management - Total assets decreased from $2,120,960 thousand as of December 31, 2024, to $1,948,597 thousand as of September 30, 2025, representing a decline of approximately 8.1%[33]. - Total current liabilities decreased from $595,678 thousand as of December 31, 2024, to $456,588 thousand as of September 30, 2025, a reduction of approximately 23.4%[33]. - Total stockholders' equity decreased from $1,243,313 thousand as of December 31, 2024, to $1,220,902 thousand as of September 30, 2025, a decrease of approximately 1.8%[33]. Expenses and Costs - Operating expenses totaled $126.3 million in Q3 2025, an increase from $115.7 million in Q3 2024, primarily driven by higher selling, general, and administrative costs[31]. - Share-based compensation expense for Q3 2025 was $11,210,000, slightly down from $11,605,000 in Q3 2024[39]. - The company incurred $2,566,000 in restructuring costs related to EnlivenHealth during the nine months ended September 30, 2025[39]. - Acquisition-related expenses for Q3 2025 were $182,000, down from $224,000 in Q3 2024[39]. - The company reported external-use software development costs of $4,528,000 for Q3 2025, compared to $4,468,000 in Q3 2024[42]. - Purchases of property and equipment for the nine months ended September 30, 2025, totaled $32,706,000, up from $27,376,000 in the same period of 2024[42].